Ontology highlight
ABSTRACT:
SUBMITTER: Ma CX
PROVIDER: S-EPMC4818722 | biostudies-literature | 2016 Apr
REPOSITORIES: biostudies-literature
Ma Cynthia X CX Luo Jingqin J Naughton Michael M Ademuyiwa Foluso F Suresh Rama R Griffith Malachi M Griffith Obi L OL Skidmore Zachary L ZL Spies Nicholas C NC Ramu Avinash A Trani Lee L Pluard Timothy T Nagaraj Gayathri G Thomas Shana S Guo Zhanfang Z Hoog Jeremy J Han Jing J Mardis Elaine E Lockhart Craig C Ellis Matthew J MJ
Clinical cancer research : an official journal of the American Association for Cancer Research 20151112 7
<h4>Purpose</h4>This trial was conducted to determine the maximum tolerated dose (MTD) and preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in postmenopausal women with metastatic estrogen receptor positive (ER(+)) breast cancer.<h4>Experimental design</h4>Phase IA employed a 3+3 design to determine the MTD of buparlisib daily plus fulvestrant. Subsequent cohorts (phase IB and cohort C) evaluated intermittent (5/7-day) and continuous dosing of buparlisib ( ...[more]